| Lupus Erythematosus, Systemic
Benlysta vs Saphnelo
Side-by-side clinical, coverage, and cost comparison for lupus erythematosus, systemic.Deep comparison between: Benlysta vs Saphnelo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSaphnelo has a higher rate of injection site reactions vs Benlysta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Saphnelo but not Benlysta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Benlysta
Saphnelo
At A Glance
IV infusion or SC injection
Weekly or every 4 weeks
BLyS inhibitor
IV infusion
Every 4 weeks
Type I interferon receptor antagonist
Indications
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Lupus Erythematosus, Systemic
Dosing
Lupus Erythematosus, Systemic IV: 10 mg/kg at 2-week intervals for first 3 doses then every 4 weeks as a 1-hour infusion; SC adults and pediatric >=40 kg: 200 mg once weekly; SC pediatric 15 to <40 kg: 200 mg once every 2 weeks.
Lupus Nephritis IV: 10 mg/kg at 2-week intervals for first 3 doses then every 4 weeks as a 1-hour infusion; SC adults and pediatric >=40 kg: 400 mg once weekly for 4 doses then 200 mg once weekly; SC pediatric 15 to <40 kg: 200 mg once weekly for 4 doses then 200 mg once every 2 weeks.
Lupus Erythematosus, Systemic 300 mg as an intravenous infusion over 30 minutes every 4 weeks; if a dose is missed, administer as soon as possible with a minimum interval of 14 days between infusions.
Contraindications
- Previous anaphylaxis with belimumab
- History of anaphylaxis with anifrolumab-fnia
Adverse Reactions
Most common (>=3%) Nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, cystitis, leukopenia, gastroenteritis viral
Serious Serious infections, hypersensitivity reactions including anaphylaxis, depression and suicidality, malignancy
Postmarketing Fatal anaphylaxis
Most common (>=2%) Upper respiratory tract infection, bronchitis, infusion-related reactions, herpes zoster, cough, respiratory tract infection, hypersensitivity
Serious Serious infections (including pneumonia), herpes zoster with multidermatomal or disseminated presentation, hypersensitivity reactions including anaphylaxis and angioedema, malignancies
Postmarketing Arthralgia
Pharmacology
BENLYSTA is a BLyS-specific inhibitor; a human IgG1lambda monoclonal antibody that blocks binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells, thereby inhibiting survival of B cells including autoreactive B cells and reducing their differentiation into immunoglobulin-producing plasma cells.
Anifrolumab-fnia is a human IgG1kappa monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1), blocking type I IFN signaling and downstream inflammatory and immunological processes; it also induces internalization of IFNAR1, reducing cell surface receptor availability.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Benlysta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (0/12)
Saphnelo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Benlysta
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (3/8) · Qty limit (0/8)
Saphnelo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Benlysta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Saphnelo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Lupus: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Lupus: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BenlystaView full Benlysta profile
SaphneloView full Saphnelo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.